Guggenheim analyst Michael Schmidt downgraded Merus (MRUS) to Neutral from Buy with a price target of $97, down from $109, after the company agreed to be acquired by Genmab (GMAB) is an all-cash transaction valued at $8.0B, or $97 per share
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRUS: